Skip to main content
PMC home page
The EMBO Journal logoLink to The EMBO Journal
. 1998 Jun 15;17(12):3317–3325. doi: 10.1093/emboj/17.12.3317

Antagonism in the human mineralocorticoid receptor.

J Fagart 1, J M Wurtz 1, A Souque 1, C Hellal-Levy 1, D Moras 1, M E Rafestin-Oblin 1
PMCID: PMC1170670  PMID: 9628869

Abstract

Key residues of the human mineralocorticoid receptor (hMR) involved in the recognition of agonist and antagonist ligands were identified by alanine-scanning mutagenesis based on a homology model of the hMR ligand-binding domain. They were tested for their transactivation capacity and ability to bind agonists (aldosterone, cortisol) and antagonists (progesterone, RU26752). The three-dimensional model reveals two polar sites located at the extremities of the elongated hydrophobic ligand-binding pocket. Mutations of Gln776 and Arg817 in site I reduce the affinity of hMR for both agonists and antagonists and affect the capacity of hMR to activate transcription, suggesting that the C3-ketone group, common to all ligands, is anchored by these two residues conserved within the nuclear steroid receptor family. In contrast, mutations of Asn770 and Thr945 in the opposite site only affect the binding of agonists bearing the C21-hydroxyl group. The binding of hMR antagonists that exhibit a smaller size and faster off-rate kinetics compared with agonists is not affected. In the light of the hMR homology model, a new mechanism of antagonism is proposed in which the AF2-AD core region is destabilized by the loss of contacts between the antagonist and the helix H12 region.

Full Text

The Full Text of this article is available as a PDF (659.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arriza J. L., Simerly R. B., Swanson L. W., Evans R. M. The neuronal mineralocorticoid receptor as a mediator of glucocorticoid response. Neuron. 1988 Nov;1(9):887–900. doi: 10.1016/0896-6273(88)90136-5. [DOI] [PubMed] [Google Scholar]
  2. Arriza J. L., Weinberger C., Cerelli G., Glaser T. M., Handelin B. L., Housman D. E., Evans R. M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science. 1987 Jul 17;237(4812):268–275. doi: 10.1126/science.3037703. [DOI] [PubMed] [Google Scholar]
  3. Barton G. J. ALSCRIPT: a tool to format multiple sequence alignments. Protein Eng. 1993 Jan;6(1):37–40. doi: 10.1093/protein/6.1.37. [DOI] [PubMed] [Google Scholar]
  4. Binart N., Lombes M., Rafestin-Oblin M. E., Baulieu E. E. Characterization of human mineralocorticosteroid receptor expressed in the baculovirus system. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10681–10685. doi: 10.1073/pnas.88.23.10681. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature. 1995 Jun 1;375(6530):377–382. doi: 10.1038/375377a0. [DOI] [PubMed] [Google Scholar]
  6. Brzozowski A. M., Pike A. C., Dauter Z., Hubbard R. E., Bonn T., Engström O., Ohman L., Greene G. L., Gustafsson J. A., Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997 Oct 16;389(6652):753–758. doi: 10.1038/39645. [DOI] [PubMed] [Google Scholar]
  7. Carlstedt-Duke J., Strömstedt P. E., Persson B., Cederlund E., Gustafsson J. A., Jörnvall H. Identification of hormone-interacting amino acid residues within the steroid-binding domain of the glucocorticoid receptor in relation to other steroid hormone receptors. J Biol Chem. 1988 May 15;263(14):6842–6846. [PubMed] [Google Scholar]
  8. Claire M., Rafestin-Oblin M. E., Michaud A., Corvol P., Venot A., Roth-Meyer C., Boisvieux J. F., Mallet A. Statistical test of models and computerised parameter estimation for aldosterone binding in rat kidney. FEBS Lett. 1978 Apr 15;88(2):295–299. doi: 10.1016/0014-5793(78)80197-5. [DOI] [PubMed] [Google Scholar]
  9. Connolly M. L. The molecular surface package. J Mol Graph. 1993 Jun;11(2):139–141. doi: 10.1016/0263-7855(93)87010-3. [DOI] [PubMed] [Google Scholar]
  10. Corvol P., Claire M., Oblin M. E., Geering K., Rossier B. Mechanism of the antimineralocorticoid effects of spirolactones. Kidney Int. 1981 Jul;20(1):1–6. doi: 10.1038/ki.1981.97. [DOI] [PubMed] [Google Scholar]
  11. Couette B., Fagart J., Jalaguier S., Lombes M., Souque A., Rafestin-Oblin M. E. Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. Biochem J. 1996 Apr 15;315(Pt 2):421–427. doi: 10.1042/bj3150421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Couette B., Lombes M., Baulieu E. E., Rafestin-Oblin M. E. Aldosterone antagonists destabilize the mineralocorticosteroid receptor. Biochem J. 1992 Mar 15;282(Pt 3):697–702. doi: 10.1042/bj2820697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Evans R. M. The steroid and thyroid hormone receptor superfamily. Science. 1988 May 13;240(4854):889–895. doi: 10.1126/science.3283939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Evans S. V. SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. J Mol Graph. 1993 Jun;11(2):134-8, 127-8. doi: 10.1016/0263-7855(93)87009-t. [DOI] [PubMed] [Google Scholar]
  15. Hendlich M., Lackner P., Weitckus S., Floeckner H., Froschauer R., Gottsbacher K., Casari G., Sippl M. J. Identification of native protein folds amongst a large number of incorrect models. The calculation of low energy conformations from potentials of mean force. J Mol Biol. 1990 Nov 5;216(1):167–180. doi: 10.1016/S0022-2836(05)80068-3. [DOI] [PubMed] [Google Scholar]
  16. Herbomel P., Bourachot B., Yaniv M. Two distinct enhancers with different cell specificities coexist in the regulatory region of polyoma. Cell. 1984 Dec;39(3 Pt 2):653–662. doi: 10.1016/0092-8674(84)90472-0. [DOI] [PubMed] [Google Scholar]
  17. Horisberger J. D., Rossier B. C. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension. 1992 Mar;19(3):221–227. doi: 10.1161/01.hyp.19.3.221. [DOI] [PubMed] [Google Scholar]
  18. Jones T. A., Zou J. Y., Cowan S. W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A. 1991 Mar 1;47(Pt 2):110–119. doi: 10.1107/s0108767390010224. [DOI] [PubMed] [Google Scholar]
  19. Klaholz B. P., Renaud J. P., Mitschler A., Zusi C., Chambon P., Gronemeyer H., Moras D. Conformational adaptation of agonists to the human nuclear receptor RAR gamma. Nat Struct Biol. 1998 Mar;5(3):199–202. doi: 10.1038/nsb0398-199. [DOI] [PubMed] [Google Scholar]
  20. Kleywegt G. J., Jones T. A. Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr D Biol Crystallogr. 1994 Mar 1;50(Pt 2):178–185. doi: 10.1107/S0907444993011333. [DOI] [PubMed] [Google Scholar]
  21. Liu W., Wang J., Sauter N. K., Pearce D. Steroid receptor heterodimerization demonstrated in vitro and in vivo. Proc Natl Acad Sci U S A. 1995 Dec 19;92(26):12480–12484. doi: 10.1073/pnas.92.26.12480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lombes M., Kenouch S., Souque A., Farman N., Rafestin-Oblin M. E. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11 beta-hydroxysteroid dehydrogenase. Endocrinology. 1994 Sep;135(3):834–840. doi: 10.1210/endo.135.3.8070376. [DOI] [PubMed] [Google Scholar]
  23. Lombès M., Binart N., Oblin M. E., Joulin V., Baulieu E. E. Characterization of the interaction of the human mineralocorticosteroid receptor with hormone response elements. Biochem J. 1993 Jun 1;292(Pt 2):577–583. doi: 10.1042/bj2920577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mangelsdorf D. J., Thummel C., Beato M., Herrlich P., Schütz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P. The nuclear receptor superfamily: the second decade. Cell. 1995 Dec 15;83(6):835–839. doi: 10.1016/0092-8674(95)90199-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Nicholls A., Sharp K. A., Honig B. Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins. 1991;11(4):281–296. doi: 10.1002/prot.340110407. [DOI] [PubMed] [Google Scholar]
  26. Rafestin-Oblin M. E., Lombes M., Couette B., Baulieu E. E. Differences between aldosterone and its antagonists in binding kinetics and ligand-induced hsp90 release from mineralocorticosteroid receptor. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):815–821. doi: 10.1016/0960-0760(92)90430-q. [DOI] [PubMed] [Google Scholar]
  27. Renaud J. P., Rochel N., Ruff M., Vivat V., Chambon P., Gronemeyer H., Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature. 1995 Dec 14;378(6558):681–689. doi: 10.1038/378681a0. [DOI] [PubMed] [Google Scholar]
  28. Ribeiro R. C., Kushner P. J., Baxter J. D. The nuclear hormone receptor gene superfamily. Annu Rev Med. 1995;46:443–453. doi: 10.1146/annurev.med.46.1.443. [DOI] [PubMed] [Google Scholar]
  29. Rousseau G. G., Baxter J. D., Tomkins G. M. Glucocorticoid receptors: relations between steroid binding and biological effects. J Mol Biol. 1972 Jun 14;67(1):99–115. doi: 10.1016/0022-2836(72)90389-0. [DOI] [PubMed] [Google Scholar]
  30. Rupprecht R., Reul J. M., van Steensel B., Spengler D., Söder M., Berning B., Holsboer F., Damm K. Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol. 1993 Oct 15;247(2):145–154. doi: 10.1016/0922-4106(93)90072-h. [DOI] [PubMed] [Google Scholar]
  31. Sali A., Blundell T. L. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993 Dec 5;234(3):779–815. doi: 10.1006/jmbi.1993.1626. [DOI] [PubMed] [Google Scholar]
  32. Souque A., Fagart J., Couette B., Davioud E., Sobrio F., Marquet A., Rafestin-Oblin M. E. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology. 1995 Dec;136(12):5651–5658. doi: 10.1210/endo.136.12.7588320. [DOI] [PubMed] [Google Scholar]
  33. Souque A., Fagart J., Couette B., Rafestin-Oblin M. E. Sulfhydryl groups are involved in the binding of agonists and antagonists to the human mineralocorticoid receptor. J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):315–321. doi: 10.1016/0960-0760(95)00278-2. [DOI] [PubMed] [Google Scholar]
  34. Strömstedt P. E., Berkenstam A., Jörnvall H., Gustafsson J. A., Carlstedt-Duke J. Radiosequence analysis of the human progestin receptor charged with [3H]promegestone. A comparison with the glucocorticoid receptor. J Biol Chem. 1990 Aug 5;265(22):12973–12977. [PubMed] [Google Scholar]
  35. Sutanto W., de Kloet E. R. Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects. Med Res Rev. 1991 Nov;11(6):617–639. doi: 10.1002/med.2610110604. [DOI] [PubMed] [Google Scholar]
  36. Thompson J. D., Higgins D. G., Gibson T. J. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994 Nov 11;22(22):4673–4680. doi: 10.1093/nar/22.22.4673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Trapp T., Holsboer F. Heterodimerization between mineralocorticoid and glucocorticoid receptors increases the functional diversity of corticosteroid action. Trends Pharmacol Sci. 1996 Apr;17(4):145–149. doi: 10.1016/0165-6147(96)81590-2. [DOI] [PubMed] [Google Scholar]
  38. Trapp T., Holsboer F. Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem Biophys Res Commun. 1995 Oct 4;215(1):286–291. doi: 10.1006/bbrc.1995.2464. [DOI] [PubMed] [Google Scholar]
  39. Tsai M. J., O'Malley B. W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem. 1994;63:451–486. doi: 10.1146/annurev.bi.63.070194.002315. [DOI] [PubMed] [Google Scholar]
  40. Ulmann A., Bertagna C., Le Go A., Husson J. M., Tache A., Sassano P., Menard J., Corvol P. Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism. Eur J Clin Pharmacol. 1985;28(5):531–535. doi: 10.1007/BF00544063. [DOI] [PubMed] [Google Scholar]
  41. Wagner R. L., Apriletti J. W., McGrath M. E., West B. L., Baxter J. D., Fletterick R. J. A structural role for hormone in the thyroid hormone receptor. Nature. 1995 Dec 14;378(6558):690–697. doi: 10.1038/378690a0. [DOI] [PubMed] [Google Scholar]
  42. Wambach G., Higgins J. R. Antimineralocorticoid action of progesterone in the rat: correlation of the effect on electrolyte excretion and interaction with renal mineralocorticoid receptors. Endocrinology. 1978 Jun;102(6):1686–1693. doi: 10.1210/endo-102-6-1686. [DOI] [PubMed] [Google Scholar]
  43. Wurtz J. M., Bourguet W., Renaud J. P., Vivat V., Chambon P., Moras D., Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol. 1996 Jan;3(1):87–94. doi: 10.1038/nsb0196-87. [DOI] [PubMed] [Google Scholar]
  44. de Wet J. R., Wood K. V., DeLuca M., Helinski D. R., Subramani S. Firefly luciferase gene: structure and expression in mammalian cells. Mol Cell Biol. 1987 Feb;7(2):725–737. doi: 10.1128/mcb.7.2.725. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES